8:00 am Pre-Registration
8:00 am — 9:45 am EXHIBIT HALL OPEN

8:30 AM - 9:30 AM PRE-CONGRESS CME SYMPOSIUM:

SUPPORTED BY: AMARIN

Yehuda Handelsman, MD

Matthew J. Budoff, MD

Peter Toth, MD



AM FRE-CONGRESS CME STMF OSIUM.

THE EVOLVING THERAPEUTIC ROLE OF ICOSAPENT ETHYL- IPE IN ASCVD AND BEYOND

Chair: Yehuda Handelsman, MD

8:30 am Introduction - TGL & CVD Risk | Pre-CME Questions

8:40 am The Role of Icosapent Ethyl in Atherosclerosis CVD & Stroke

8:55 am Beyond Cardiovascular Disease: Potential Future Uses of Icosapent Ethyl

9:10 am Panel Discussion and Q&A: Omega-3 Fatty Acid Reality and Myth

Panel: Yehuda Handelsman, MD • Matthew J. Budoff, MD • Peter Toth, MD

Moderator: Yehuda Handelsman, MD

9:25 am — 9:30 am Concluding Remarks & Post CME Questions

9:40 am — 10:00 am Welcome & Introduction | Pre-CME Questions

SESSION 1 COVID-1	9
-------------------	---

Chairs: Paul Jellinger, MD • George Grunberger, MD

10:00 am MRAs for Prevention or Treatment of COVID-19 Christopher Wilcox, MD, PhD
10:15 am Cardiac Involvement and Management Approaches in Covid-19 Biykem Bozkurt, MD, PhD
10:30 am SGLT2i in COVID-19: DARE-19 Mikhail N. Kosiborod. MD

10:45 am — 11:05 am Panel Discussion and Q&A

SESSION 2 CONTEMPORARY APPROACH TO ASCVD IN DM

Chairs: Laurence Sperling, MD • Vivian A. Fonseca, MD

11:05 am Navigating Cardiometabolic Risk: Current and Emerging Approaches in the

Diagnosis and Treatment of NAFLD

11:20 am The Interaction of Optimal Medical Therapy and Revascularization Strategies in

Patients with Diabetes and Coronary Artery Disease

11:35 am Anti Coagulation Agents in the Prevention of ASCVD in DM Peter J. Grant, MD

11:50 am The Role of DM Meds in Stroke Prevention

12:05 pm — 12:25 pm Panel Discussion and Q&A

12:25 pm - 1:20 pm LUNCH BREAK

12:30 pm — 1:15 pm PRODUCT THEATER Non-CME Industry Supported Session

Add on Efficacy. Oral, Nonstatin Therapies for Lowering LDL-C

Supported by: Esperion

Norman Lepor, MD



Christos Mantzoros, MD

Michael E. Farkouh, MD

Silvio E. Inzucchi, MD

SESSION 3 JOINT SYMPOSIUM WITH CIRCULATION

Chair: Brendan Everett, MD

duction

1:25 pm Effect of SGLT2 inhibition on Atrial Fibrillation Stephen D. Wiviott, MD 1:40 pm Regulatory Guidance on Newer Anti-Hyperglycemic Agents Neha J. Pagidipati, MD

1:55 pm Body Composition and Risk of CVD in Diabetes Kershaw V. Patel, MD

2:10 pm Gestational Diabetes, Subsequent Glucose Tolerance and Coronary Artery Calcium in Women: The CARDIA Study Erica P. Gunderson, PhD 2:25 pm Finerenone and CV Outcomes in CKD and Type 2 Diabetes Rajiv Agarwal, MD

2:40 pm - 3:00 pm Panel Discussion and Q&A

FRIDAY SEPTEMBER 10, 2021 (cont.)

SESSION 4 DM & CVD IN DIVERSE POPULATIONS

Chairs: Jane EB Reusch, MD • Norman Lepor, MD

3:00 pm Cardiovascular Disease in South Asians Martha Gulati, MD
3:15 pm CVD in African Americans with Diabetes Sam Dagogo-Jack, MD

3:30 pm — 3:40 pm Panel Discussion and Q&A

3:40 pm - 4:10 pm REFRESHMENT BREAK

SESSION 5 IMAGING OF ATHEROSCLEROSIS

Chairs: Michael Farkouh, MD • Erin D. Michos, MD

4:10 pm The Role of CV Risk Assessment of Asymptomatic Patients with Diabetes Matthew J. Budoff, MD
4:25 pm The Best Imaging to Identify Atherosclerosis in Women Leslee J. Shaw, PhD

DEBATE: THE BEST MODALITY TO PREDICT CV

4:40 pmBiomarkersBrendan Everett, MD4:55 pmImagingNorman Lepor, MD

5:10 pm - 5:30 pm Panel Discussion and Q&A

5:30 pm -6:30 pm DAY 1 SUMMARY SESSION & POST-CME QUESTIONS

Yehuda Handelsman, MD ● Mikhail Kosiborod, MD ● Matthew Budoff, MD ● Erin D. Michos, MD ● Vivian A. Fonseca, MD ● George Grunberger, MD

6:30 pm - 7:30 pm WELCOME AND POSTER RECEPTION

Online (Virtual) Only

6:30 pm- 7:15 pm PRODUCT THEATER Non-CME Industry Supported Session

Three Critical Concepts for Balancing ASCVD and Metabolic Risk Management

Supported by: Novartis Pharmaceuticals Corporation

Mark Stampehl, MD



7:30 PM — 9:00 PM DINNER CME SYMPOSIUM:

DIABETES KIDNEY DISEASE NEXT FRONTIER IN THERAPY

Chair: Yehuda Handelsman, MD • Mikhail Kosiborod, MD

7:30 pm Introduction & Pre-CME Questions

7:35 pm Diabetic Kidney Disease Epidemiology, Pathophysiology and Current Treatment

7:55 pm The New Class of Non Steroidal MRA (focus on Finerenone)

8:15 pm The Evolving Management of CKD and HF

 $8:35\ pm$ Panel Discussion and Q&A: Emerging Management of DM and CKD — Case-Based

Panel: Rajiv Agarwal, MD • George L. Bakris, MD • Mikhail Kosiborod, MD

Moderator: Yehuda Handelsman, MD

8:55 pm — 9:00 pm Concluding Remarks & Post-CME Questions

SUPPORTED BY: BAYER

Yehuda Handelsman, MD George L. Bakris, MD Rajiv Agarwal, MD Mikhail Kosiborod, MD

SATURDAY SEPTEMBER 11, 2021

7:00 am — 8:00 am EXHIBIT HALL OPEN | Continental Breakfast

7:00 am - 7:45 am PRODUCT THEATER Non-CME Industry Supported Session

Jardiance® (empagliflozin) tablets: A Review of the Latest Data Johanna Contreras, MD

Supported by: Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC



8:00 am - 8:10 am Pre-CME Questions

SESSION 6	OBESITY, DIABETES AND THE HEART	
	Chairs: Robert J. Chilton, DO ● Richard Pratley, MD	
8:10 am	Diabetes, Obesity and the Heart: Evidence from Epidemiologic Studies	Elizabeth Selvin, PhD
8:25 am	Pharmacologic Strategies in Obesity Effect on Metabolic & CV Risk	Donna H. Ryan, MD
8:40 am	Contemporary Diets in the Prevention of CVD	Pam R. Taub, MD
8:55 am — 9:10 an	n Panel Discussion and Q&A	

SESSION 7	GUIDELINES UPDATE	
	Chairs: Jane EB Reusch, MD ● Matthew J. Budoff, MD	
9:10 am	AHA Consensus: Management of Stable Coronary Disease in People with Diabetes	Suzanne V. Arnold, MD
9:25 am	ESC Prevention Guidelines	Kausik Ray, MD
9:40 am	ADA Standard of Care Update	Jennifer Green, MD
9:55 am — 10-:1	5 am Panel Discussion and Q&A	

10:15 am - 10:45 am REFRESHMENT BREAK AT EXHIBIT HALL

SESSION 8	RECENT DIABETES PUBLICATIONS IN CARDIOLOGY	
	Chair: Michael E. Farkouh, MD	
10:45 am	Introduction	
10:50 am	Coronavirus and Cardiometabolic Syndrome: JACC Focus Seminar	Jeffrey I. Mechanick, MD
11:05 am	Influence of LDL-C on Cardiovascular Outcomes in Patients With Diabetes Undergoing Coron	ary Revascularization Lucas Godoy, MD
11:20 am	2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduc	tion
	in Patients With Type 2 Diabetes: A Report of the American College of Cardiology	Melissa L. Magwire, RN,MSN, CDES
11:35 am	Role of Biomarker in Heart Failure Risk Prediction in Individuals with Dysglycemia	Ambarish Pandey, MD
11:50 am	Duration of Diabetes and Incident Heart Failure	Erin D. Michos, MD

12:05 pm — 12:20 pm Panel Discussion

12:20 pm - 1:30 pm LUNCH BREAK

12:30 pm — 1:20 pm PRODUCT THEATER Non-CME Industry Supported Session

A Focus on Very High-Risk Patients in the Acute Setting: Understanding Plaque and Prioritizing LDL-C

Michael J. Blaha MD MPH Supported by: Amgen



SESSION 9	ADVANCED TECHNOLOGIES	
	Chairs: Daniel Einhorn, MD ● Martha Gulati, MD	
1:30 pm	CGM Impact on CVD — focus on TIR	George Grunberger, MD
1:45 pm	CGM Role in T2D on Lifestyle +/- Oral Medications	Viral Shah, MD
2:00 pm	Impact of Glucose Variability on CVD	Richard E. Pratley, MD
2:15 pm — 2:30	pm Panel Discussion and Q&A	

SATURDAY SEPTEMBER 11, 2021 (cont.)

2:30 pm AWARD PRESENTATION "LUMINARY IN CARDIOMETABOLIC MEDICINE"

2:35 pm Lipids, Obesity, Metabolic Syndrome, Diabetes and the Heart - My Professional Journey

Robert H. Eckel, MD



3:05 pm — 3:15 pm Q&A

3:15 pm - 3:45 pm REFRESHMENT BREAK AT EXHIBIT HALL

SESSION 10 CVOT

Chairs: Mikhail Kosiborod, MD • Matthew R. Weir, MD

3:45 pm Update on CVOT Deepak L. Bhatt, MD

DEBATE: SHOULD BRAND NEW DATA BE RAPIDLY ADOPTED BY GUIDELINES?

 4:15 pm
 Yes

 4:30 pm
 No

 Robert J. Chilton, DO

 Sanjay Kaul, MD

4:45 pm — 5:05 pm Panel Discussion and Q&A

SESSION 11 SLEEP APNEA AND METABOLISM

Chairs: Christian W. Mende, MD • Neha Pagidipati, MD

5:05 pm OSA Hyperglycemia and Diabetes Naresh Punjabi, MD
5:20 pm Sleep Apnea and Cardiovascular Disease: Evidence, Mechanism, and Treatment Henry Klar Yagqi, MD

5:35 pm - 5:45 pm Panel Discussion and Q&A

5:45 pm — 6:45 pm DAY 2 SUMMARY SESSION & POST-CME QUESTIONS

Yehuda Handelsman, MD • Sanjay Kaul, MD • Richard E. Pratley, MD • Jane EB Reusch, MD • Michael E. Farkouh, MD • Daniel Einhorn, MD

6:45 PM — 8:30 PM DINNER CME SYMPOSIUM:

SUPPORTED BY: ASTRAZENECA

Yehuda Handelsman, MD

Ian De Boer, MD

Robert J. Chilton, DO

Robert D. Toto, MD



KIDNEY DISEASE AND THE HEART IN DIABETES & BEYOND – CIRCA 2021

Chairs: Matthew Weir, MD • Yehuda Handelsman, MD

7:00 pm Introduction & Pre-CME Questions

7:05 pm CKD Impact on Health and Disease

7:25 pm Contemporary Approach to Prevention Management of Heart Failure

7:45 pm Emerging Concepts in Management of CKD — the Prevention of Morbidity and Mortality

8:05 pm Panel Discussion and Q&A: Kidney and Heart Diseases — Causality Dilemma

Panel: Yehuda Handelsman, MD • Ian De Boer, MD • Robert J. Chilton, DO • Robert D. Toto, MD

Moderator: Matthew Weir, MD

8:25 pm — 8:30 pm Concluding Remarks & Post-CME Questions

SUNDAY SEPTEMBER 12, 2021

7:00 am - 8:00 am Registration | Continental Breakfast

7:00 gm - 8:00 gm ABSTRACT ORAL PRESENTATIONS

Abstracts are published in the American Heart Journal, Editor-in-Chief: Daniel Mark, MD, MPH

Chair: George Grunberger, MD

Abstract Committee: Zachary T. Bloomgarden, MD ● Matthew J. Budoff, MD ● Vivian A. Fonseca, MD ●

Norman E. Lepor, MD • Derek LeRoith, MD, PhD • Laurence Sperling, MD

Refreshments will be served

8:00 am - 8:10 am Pre-CME Questions

8:10 am — 8:15 am Oral Abstract Winner Award Presentation

George Grunberger, MD

SUNDAY SEPTEMBER 12, 2021 (cont.)

SESSION 12	MANAGEMENT OF DIABETES CIRCA 2021	
	Chairs: Silvio E. Inzucchi, MD ● Ralph A. DeFronzo, MD	
8:15 am	100 Years of Insulin and the Heart	Vivian A. Fonseca, MD
8:30 am	Early and Intensive Management of Diabetes with SGLT2i & GLP1-ra	Stefano Del Prato, MD
8:45 am	The Metabolic Impact of Hypoglycemia & Contemporary Approach to Management	Daniel Einhorn, MD
9:00 am — 9:15 a	m Panel Discussion and Q&A	

SESSION 13	HEART DISEASE IN WOMEN	
	Chairs: Vivian Fonseca, MD ● Laurence Sperling, MD	
9:15 am	CVD and PCOS — Smoke versus Fire	Andrea Dunaif, MD
9:30 am	Link Between Migraine & CVD Implications for Management	Gina P. Lundberg, MD
9:45 am	Sex Hormone Impact on Heart Failure in Men and Post-Menopausal Women	Erin D. Michos, MD
10.00 am _ 10.20	am Panal Discussion and OSA	

10:20 am - 10:35 am REFRESHMENT BREAK

SESSION 14	DYSLIPIDEMIA AND ASCVD	
	Chairs: Neha J. Pagidipati, MD ● Paul Jellinger, MD	
10:35 am	Role of New Agents in Managing Dyslipidemia of DM to Reduce CVD	Christie M. Ballantyne, MD
10:50 am	Management of Dyslipidemia in Young People with Diabetes	Elaine M. Urbina, MD
11:05 am	The Subclinical Progression of Arterial Disease Evaluated by US, MRI,	
	& PET: Role of LDL-C and Other Risk Factors	Valentin Fuster, MD, PhD
11:20 am — 11:40	O am Panel Discussion and Q&A	

11:40 am - 12:35 pm LUNCH/CHECK OUT BREAK

11:45 am — 12:30 pm	PRODUCT THEATER Non-CME Industry Supported Session Hidden Hypercortisolism: What Are We Missing and Why Does It Matter?	Daniel Einhorn, MD
	Supported by: Corcept	



SESSION 15	HF & CKD OR THE CARDIORENAL SYNDROME?	
	Chairs: Martha Gulati, MD ● Christian W. Mende, MD	
12:35 pm	Kidney Disease in Diabetes: Implications for Therapy	Ralph A. DeFronzo, MD
12:50 pm	Contemporary Approach to Medications in CKD Control	Mark J. Sarnak, MD
1:05 pm	The Contemporary Role of Medications and the Heart	Laurence Sperling, MD
1:20 pm	2021 HFpEF vs. HFrEF	John McMurray, MD
1:35 pm	State-of-the-art Management of Hyperkalemia in HF & CKD	Matthew R. Weir, MD
1:50 pm	Management of HF — What Should the Guidelines Be?	Javed Butler, MD
2·05 nm — 2·30 n	Panel Discussion: Cardiorenal Syndrome Is it More than the Individual Components	

2:30 pm - 3:30 pm	DAY 3 SUMMARY SESSION & POST-CME QUESTIONS
	Yehuda Handelsman, MD • Neha Pagidipati, MD • Christian Mende, MD •
	Ralph A. DeFronzo, MD • Martha Gulati, MD • Laurence Sperling, MD